Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants
Rotavirus Vaccine
Infections, Rotavirus
Phase 3
The results of this study 111274 are summarised with study 102248 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A link to and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies.
January 2014